# Thryv Therapeutics Inc. funding rounds and investors

As of 3 Nov 2026, Thryv Therapeutics Inc. has raised $30M across 1 verified round on record; latest: $30 million Series B led by InClin, announced 3 Nov 2026.

A clinical-stage biotechnology company developing precision therapies for inherited channelopathies, cardiometabolic diseases and cardiomyopathies.

Headquarters: Canada  
Page: https://fireround.dev/companies/thryv-therapeutics

## Verified rounds

| Announced | Round | Amount | Lead investors | Other investors | Sources |
| --- | --- | --- | --- | --- | --- |
| 2026-11-03 | Series B | $30 million | InClin | adMare BioInnovations, Alexandria Venture Investments, Amplitude Ventures, CTI Life Sciences Fund, Fonds de solidarité FTQ, Investissement Québec, Lumira Ventures | [prnewswire.com](https://www.prnewswire.com/news-releases/thryv-therapeutics-announces-30-million-financing-to-launch-the-aspire-hf-study-in-patients-with-heart-failure-wave-ii-efficacy-cohort-fully-enrolled-in-long-qt-syndrome-302926937.html), [allsci.com](https://allsci.com/news/biotech/heart-failure-study-thryv-therapeutics-raises-usd), [citybiz.co](https://www.citybiz.co/article/928552/thryv-therapeutics-raises-30m-series-b-to-advance-heart-failure-drug-into-phase-2-trial) |

Source: Fireround (https://fireround.dev), an open-source funding feed. Each round is checked against the pages listed with it.